Plasma cell leukemia: from biology to treatment
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
25778450
DOI
10.1111/ejh.12533
Knihovny.cz E-resources
- Keywords
- bone marrow transplantation, bortezomib, multiple myeloma, plasma cell leukemia,
- MeSH
- Survival Analysis MeSH
- Transplantation, Autologous MeSH
- Bortezomib therapeutic use MeSH
- Antigens, CD genetics metabolism MeSH
- Chromosome Aberrations * MeSH
- Gene Expression MeSH
- Transplantation, Homologous MeSH
- Induction Chemotherapy methods MeSH
- Humans MeSH
- Multiple Myeloma genetics mortality pathology therapy MeSH
- Plasma Cells pathology MeSH
- Leukemia, Plasma Cell genetics mortality pathology therapy MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage MeSH
- Stem Cell Transplantation * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Bortezomib MeSH
- Antigens, CD MeSH
Plasma cell leukemia (PCL) is a very aggressive and rare form of malignant monoclonal gammopathy characterized by the presence of plasmocytes in peripheral blood. It is classified as primary PCL occuring 'de novo', or as secondary PCL in patients with relapsed/refractory multiple myeloma. Primary PCL is a distinct clinicopathological entity from myeloma with different cytogenetic abnormalities and molecular findings, which are usually found only in advanced multiple myeloma. The clinical course is aggressive with short remissions and reduced overall survival. The diagnostic criteria are based on the percentage (>20%) and absolute number (2 × 10(9) /L) of plasma cells in peripheral blood. After establishing diagnosis, induction therapy should begin promptly which is aimed to rapid disease control and to minimize the risk of early death. Intensive chemotherapy regimens and bortezomib-based regimens, followed by high-dose therapy with autologous stem cell transplantation, are recommended. Allogeneic transplantation can be considered in younger patients. This article reviews recent knowledge of this hematological malignancy that is associated with a very poor prognosis.
University Hospital Brno Department of Clinical Haematology Brno Czech Republic
University Hospital Ostrava Department of Haematooncology Ostrava Czech Republic
University of Ostrava Faculty of Medicine Ostrava Czech Republic
References provided by Crossref.org
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?
